Bøger udgivet af Heymanns Verlag GmbH

On June 1, the Unified Patent Court became operational and unitary patents are now available for filing.This book provides an overview of the unitary patent system and offers additional strategic considerations, especially regarding the questions:Should an "opt-out" be filed for existing European patents or not?Should the Unified Patent Court be invoked?How should proceedings before the Unified Patent Court be approached?How do I defend myself if I am attacked?It is a valuable aid for all those active in the field of patent protection in Europe, since, unlike a commentary, it provides comprehensive and concrete considerations from a strategic point of view and derives concrete proposals for action from them.In addition, several chapters of the book are devoted to the enforcement of judgments of the Unified Patent Court as well as to the comparison between the Unified Patent Court and the patent jurisdiction of the member states. For this purpose, well-known guest authors could be won.New:Consideration of all relevant amendments to the lawOverview of national regulations in China, Korea, Japan and the USAAppendix with relevant legal texts Author:Prof. Dr. Aloys Hüttermann is a patent attorney in Düsseldorf, co-editor of the planned commentary on the unitary patent system and known as a specialist in this field through numerous lectures.

»From Clones to Claims« has evolved as a reaction to the ready internet availability of all decisions of the Boards of Appeal of the European Patent Office (EPO). While the increased availability is one thing, using the information in daily practice is another. This translation is the aim of the 7th edition of this book. It has become a guide through the available decisions not only of Boards 3.3.04 and 3.3.08 - the initial biotech Boards - but also of Boards 3.3.01 and 3.3.02, which have meanwhile also begun to hear biotech cases. This reflects the overwhelming development and expansion of biotech into the field of biopharmaceuticals, for example, the advent of antibody drugs against several types of life-threatening cancer and chronic diseases, such as rheumatoid arthritis. One of the best current examples of the importance of biopharmaceuticals was the virtually immediate advent of powerful vaccines against the causative agent of the corona (SARS-CoV-2/Covid-19) pandemic. »From Clones to Claims« contains extra chapters on the patenting of viruses - and related vaccines. This is just one example of the chapters in the expanded version. This 7th edition also contains other supplemental chapters in view of recent developments in science and related jurisprudence. For example, new or substantially revised chapters include a new, more elaborate chapter on SPCs; a new chapter on plausibility, with express consideration of pending case G 2/21; as well as new chapters on next generation sequencing technologies and personalized medicines/companion diagnostics. A further new chapter addresses CRISPR, outlining and discussing the complex pattern of oppositions and appeals in the EPO concerning this revolutionary, Nobel prize winning technology. Thus, the current jurisprudence of the Boards of Appeal of the EPO is systematically organized according to the following topics:Products of Nature: What is Patentable in the EPO (compounds, stem cells, plants, etc.)The Person Skilled in the ArtThe Principles Applied by the Technical Boards in Assessing the Disclosure of a Document and their ImplicationsThe Principles Applied by the Technical Boards in Claim ConstructionPlausibility as a Means to Assess Quid Pro QuoThe Principles of Patenting Medical and Diagnostic UsesPatenting Nucleic Acid InventionsPatenting Protein InventionsPatenting Antibody InventionsPatenting Microorganisms and Fermentation TechnologiesPatenting VirusesPatenting Stem Cells and Cell-based TherapeuticsPatenting Nucleic Acid Amplification TechnologiesPatenting Nucleic Acid Modification Technologies: CRISPR et al.Patenting Next Generation Sequencing TechnologiesPatenting Personalized Medicines and Companion DiagnosticsPatenting Plants and AnimalsPriority - Hurdles of Same Subject Matter and Legal EntitlementDepositHow to draft a European Patent Application and ClaimsA Brief Introduction to the Extension of Patent TermsAs is evident, this expanded version of »From Clones to Claims« solely focuses on EPO Appeal Board jurisprudence and SPCs. It no longer addresses jurisprudence from the US or Japan as a consequence of the technically limited space in such a product. Thus, the new version is a detailed guide on how to prepare European patent applications in any particular field of biopharmaceuticals and how to best defend the European patents once granted. Given this, the book is not only useful for advanced practitioners, but also for beginners as an introduction into and an orientation to the field of biotechnology patents.Given the book's clear language and systematic structure, the EPO's jurisprudence is

This book is a practical guide for candidates on how to tackle the opposition paper C of the European Qualifying Examination (EQE), one of the more difficult papers judging by the overall results. It also provides qualified European patent attorneys with useful information on how to write, or defend against, an opposition, in particular the general practice at the EPO regarding the analysis of documents and possible approaches for drafting novelty and inventive step objections.The book tackles the problems of time-management, claim and document analysis, choosing the correct attacks and the argumentation required in the notice of opposition in the context of two alternative methodologies for solving paper C. The first is the well-known table with claim features against the prior art documents, which over the years seems to work less and less satisfactorily. The second is the »CEIPI« method with a written analysis of each claim on sheets of paper, useful for the notice of opposition. This method is specially adapted to paper C as it has developed over time.Further chapters describe the important topics of priority, interpretation, state of the art, inventive step, added subject-matter and ranges. For each topic, the authors first give references to relevant legal sources, then they explain the topic from the point of view of opposition/paper C, and finally they give examples from past papers, as exercise material. Throughout the book, the authors point out the interconnections between these topics, the methodologies and the argumentation required in the notice of opposition, especially for inventive step attacks. The book also includes a collection of the legal points that have come up in past papers, sorted by theme. The appendices contain a worked example of paper C 2010 as well as useful templates for candidates, including a notice of opposition in English, French and German.Revised and updated:Fully revised chapter on the methods to tackle Paper C.Fully revised chapters in the light of more recent examination papers, the latest guidelines for examination and the revised implementing provisions for the EQE as of 2013.Updated exam paper (C 2010)Contains standard phrases for the Notice of Opposition in all three official languages (EN, FR, DE)Contains the model solution for C 2010 and its supporting documents in all three official languages (English, French and German)More information on examination strategyUpdate for all the Guidelines changes since 2016 (kept up to date every year with corrigenda-sheets)Update for all the C papers since 2016Update for latest G decisions important for paper CShortcuts in the Ceipi method, if time is running shortStandard phrases have been reviewed and updated in all three languagesHow to mark up the documents of the C paper to more easily find back te required informationExplanation of hidden independent claimsUpdate on interpretation of claimsSpecial topics of interest in real life oppositionNew material on prior use and oral disclosureIssues with the validity of priority of a document cited against the patentUpdate for inventive step attacks according to the most recent C papers:- What to do with more than one possible closest prior art- Mix of technical and non-technical features and inventive step- Change necessary in closest prior art because the purpose of the invention changes from one claim to the nextContains the model solution for C 2010 and its supporting documents in all three official languages (English, French and German)Edited by: William E. Chandler, Chairman of a Technical Board of Appeal of the EPO and Hugo Meinders, former Chairm